Skip to content

NIH Distinguished Investigator

Biography

Carlos A. Zarate, M.D. is Chief, Section on the Neurobiology and Treatment of Mood Disorders and Chief of Experimental Therapeutics and Pathophysiology Branch (ETPB) at the National Institute of Mental Health, and Clinical Professor of Psychiatry and Behavioral Sciences, at The George Washington University.

Dr. Zarate completed a Fellowship in Clinical Psychopharmacology at McLean Hospital from 1992-1993, after which he remained as a staff member until 1998. At the McLean Hospital Consolidated Department of Psychiatry, Harvard Medical School, Dr. Zarate was the Director of the Bipolar and Psychotic Disorders Outpatient Services, Chair of the Pharmacy and Therapeutic Committee, and Director of the New and Experimental Clinic. From 1998 to 2000, Dr. Zarate was the Chief of the Bipolar and Psychotic Disorders Program, Associate Professor of Psychiatry, and Chair of the Grand Rounds Committee at the University of Massachusetts Medical School. In January 2001, he joined the Mood and Anxiety Disorders Program at the NIMH as Chief of the Mood Disorders Research Unit. In 2009, Dr. Zarate formed the Experimental Therapeutics and Pathophysiology Branch at the NIMH.

His achievements and awards include the Ethel-DuPont Warren Award and Livingston Awards, Consolidated Department of Psychiatry, Harvard Medical School, 1993-1994; NIH-NIMH Travel Award, 1994; American College of Neuropsychopharmacology Travel Awards, 1994 and 1995; Program for Minority Research Training in Psychiatry, American Psychiatric Association, 1996; the National Alliance for Research on Schizophrenia and Depression Young Investigator Award, 1996-1998; Outstanding Psychiatrist Research Award, Massachusetts Psychiatric Association, 1997; the Diversity and Advocacy Award, Hispanic Research Initiative Committee, NIMH, 2002; the Mentor of the Year, Intramural Research Program, NIMH, 2004; the Supervisor of the Year, NIMH,2005; the National Alliance for Research on Schizophrenia and Depression Independent Investigator Award, 2005; the NIH Director’s Award-Scientific/Medical, 2007; NIMH Directors Award, 2009; and, the Brain Behavior Research Foundation Award for Bipolar Mood Disorder Research (NARSAD), 2011

Research Interests

Dr. Zarate’s current research focus is on developing novel medications for treatment-resistant depression and bipolar disorder.  His areas of expertise include biological and pharmacological aspects of mood disorders in adults.  Dr. Zarate’s group conducts proof-of-concept studies utilizing novel compounds and biomarkers (magnetoencephalography [MEG] and polysomnography [PSG], positron emission tomography [PET], functional magnetic resonance imaging [fMRI] and magnetic resonance spectroscopy [MRS]) to identify potentially relevant drug targets and biosignatures of treatment response.  A multidisciplinary translational research team conducts the research in the ETPB. In addition, the Branch provides training to develop the next generation of clinical translational researchers.

See Dr. Zarate's current clinical research studies here.

Selected Publications

Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67:793-802. [Pubmed Link]

Nugent AC, Ballard ED, Gould TD, Park LT, Moaddel R, Brutsche NE, Zarate CA (2018) Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. Mol Psychiatry, in press (e-pub ahead of print) https://doi.org/10.1038/s41380-018-0028-2. [Pubmed Link]

Zanos P, Highland JN, Stewart BW, Georgiou P, Jenne CE, Lovett J, Morris PJ, Thomas CJ, Moaddel R, Zarate CA, Gould TD (2019). ()-hydroxynorketamine exerts mGlu receptor-dependent antidepressant actions. Proc Natl Acad Sci U S A 116, 6441-6450. https://doi.org/10.1073/pnas.1819540116. [Pubmed Link]

Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-64. [Pubmed Link]

Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KSS, Fang Y, Huang XP, Mayo CL, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA, Gould TD (2017). Zanos et al. reply. Nature 546, E4-E5. https://doi.org/10.1038/nature22085. [Pubmed Link]


Hatfield Clinical Research Center, Room 7-5342, MSC 1282
BETHESDA, MD 20814

Phone: +1 301 451 0861
Fax: +1 301 480 8792

zaratec@mail.nih.gov